Business Description
Exact Therapeutics AS
ISIN : NO0010852213
Share Class Description:
OSL:EXTX: Ordinary SharesCompare
Compare
Traded in other countries / regions
EXTX.Norway56F.Germany IPO Date
2020-07-14Description
Exact Therapeutics AS is a clinical-stage biotechnology company. It is developing Acoustic Cluster Therapy (ACT), a promising non-invasive precision health technology for targeted enhancement of therapeutics. ACT sonoporation is an approach to ultrasound-mediated, targeted drug enhancement that will amplify the clinical utility of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and neurological conditions.
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 38.11 | |||||
Equity-to-Asset | 0.74 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.03 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 12.2 | |||||
3-Year EPS without NRI Growth Rate | 11.7 | |||||
3-Year FCF Growth Rate | 9.5 | |||||
3-Year Book Growth Rate | -35.9 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 61.99 | |||||
9-Day RSI | 59.14 | |||||
14-Day RSI | 57.09 | |||||
6-1 Month Momentum % | -38.33 | |||||
12-1 Month Momentum % | -35.65 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.61 | |||||
Quick Ratio | 3.61 | |||||
Cash Ratio | 2.94 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.3 | |||||
Shareholder Yield % | 0.13 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -93.42 | |||||
ROA % | -73.74 | |||||
ROIC % | -486.96 | |||||
ROC (Joel Greenblatt) % | -989.74 | |||||
ROCE % | -91.54 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 5.65 | |||||
Price-to-Tangible-Book | 5.64 | |||||
EV-to-EBIT | -4.36 | |||||
EV-to-EBITDA | -4.55 | |||||
EV-to-FCF | -3.77 | |||||
Price-to-Net-Current-Asset-Value | 6.41 | |||||
Price-to-Net-Cash | 8.64 | |||||
Earnings Yield (Greenblatt) % | -22.91 | |||||
FCF Yield % | -18.58 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Exact Therapeutics AS Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil kr) | |||
EPS (TTM) (kr) | -1.51 | ||
Beta | 0.04 | ||
Volatility % | 72.35 | ||
14-Day RSI | 57.09 | ||
14-Day ATR (kr) | 0.347486 | ||
20-Day SMA (kr) | 7.3025 | ||
12-1 Month Momentum % | -35.65 | ||
52-Week Range (kr) | 4.8 - 20 | ||
Shares Outstanding (Mil) | 32.08 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Exact Therapeutics AS Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Exact Therapeutics AS Stock Events
Event | Date | Price(kr) | ||
---|---|---|---|---|
No Event Data |
Exact Therapeutics AS Frequently Asked Questions
What is Exact Therapeutics AS(OSL:EXTX)'s stock price today?
The current price of OSL:EXTX is kr7.95. The 52 week high of OSL:EXTX is kr20.00 and 52 week low is kr4.80.
When is next earnings date of Exact Therapeutics AS(OSL:EXTX)?
The next earnings date of Exact Therapeutics AS(OSL:EXTX) is 2024-09-19.
Does Exact Therapeutics AS(OSL:EXTX) pay dividends? If so, how much?
Exact Therapeutics AS(OSL:EXTX) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |